The malaria parasite Plasmodium falciparum employs two metallo-aminopeptidases, PfA-M1 and PfA-M17, which are essential for parasite survival. Compounds that inhibit the activity of either enzyme represent leads for the development of new antimalarial drugs. Here we report the synthesis and structure-activity relationships of a small library of phosphonic acid arginine mimetics that probe the S1 pocket of both enzymes and map the necessary interactions that would be important for a dual inhibitor
Previous studies have pinpointed the M17 leucyl aminopeptidase of Plasmodium falciparum (PfLAP) as a...
The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for t...
Malaria is one of the most prevalent human parasitic diseases and is a global health issue accountin...
The malaria parasite Plasmodium falciparum employs two metallo- aminopeptidases, PfA-M1 and PfA-M17,...
The malaria parasite Plasmodium falciparum employs two metallo-aminopeptidases, <i>Pf</i>A-M1 and <i...
Malaria remains a global health problem, and though international efforts for treatment and eradicat...
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our curr...
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to r...
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to r...
Current therapeutics and prophylactics for malaria are under severe challenge as a result of the rap...
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our curr...
Plasmodium falciparum parasites are responsible for the major global disease malaria, which results ...
<div>Current therapeutics and prophylactics for malaria are under severe challenge as a result of th...
<div><p>Malaria is a parasitic disease that remains a global health burden. The ability of the paras...
Previous studies have pinpointed the M17 leucyl aminopeptidase of Plasmodium falciparum (PfLAP) as a...
Previous studies have pinpointed the M17 leucyl aminopeptidase of Plasmodium falciparum (PfLAP) as a...
The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for t...
Malaria is one of the most prevalent human parasitic diseases and is a global health issue accountin...
The malaria parasite Plasmodium falciparum employs two metallo- aminopeptidases, PfA-M1 and PfA-M17,...
The malaria parasite Plasmodium falciparum employs two metallo-aminopeptidases, <i>Pf</i>A-M1 and <i...
Malaria remains a global health problem, and though international efforts for treatment and eradicat...
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our curr...
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to r...
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to r...
Current therapeutics and prophylactics for malaria are under severe challenge as a result of the rap...
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our curr...
Plasmodium falciparum parasites are responsible for the major global disease malaria, which results ...
<div>Current therapeutics and prophylactics for malaria are under severe challenge as a result of th...
<div><p>Malaria is a parasitic disease that remains a global health burden. The ability of the paras...
Previous studies have pinpointed the M17 leucyl aminopeptidase of Plasmodium falciparum (PfLAP) as a...
Previous studies have pinpointed the M17 leucyl aminopeptidase of Plasmodium falciparum (PfLAP) as a...
The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for t...
Malaria is one of the most prevalent human parasitic diseases and is a global health issue accountin...